In recent years, a growing understanding of myotonic dystrophy type 1 (DM1)—an often fatal, devastating, rare neuromuscular disorder that causes muscle weakness and other life-limiting ...
The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals with myotonic dystrophy type 1, or DM1, according to the manufacturer. In a press ...
Hosted on MSN29d
Dyne Therapeutics reports clinical data from its myotonic dystrophy type 1 treatmentDyne Therapeutics (NASDAQ:DYN) reported clinical data from its ongoing Phase 1/2 trial of DYNE-101 in patients with myotonic dystrophy type 1.Shares down about 22% in early trade. DYNE-101 ...
demonstrating a potential new therapeutic approach for managing this condition [1]. Furthermore, studies on granular corneal dystrophy type 2 (GCD2) have shown that phototherapeutic keratectomy ...
RESULTS: Best spectacle-corrected visual acuity improved in 79% and 62% of eyes with granular and lattice dystrophy, respectively. Spherical equivalent refraction increased by a mean of 1.3 +/- 1. ...
(RTTNews) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). Myotonic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback